Verastem doses first patient in lung cancer trial for VS-7375

July 22, 2026 4:01 PM

Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found